Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

    NEXT STORY
    Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19
    PREV STORY
    Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

    HAIFA, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a ...

    author_avatar
    NASDAQ Market News

    Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide

    author_avatar
    NASDAQ Market News

    Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients

    People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to ...

    author_avatar
    NASDAQ Market News